Search results for "pharmaceutical company"

Celltrion Secures Dominant Market Share in Asia Led by Autoimmune and Oncology Biosimilars

Celltrion Secures Dominant Market Share in Asia Led by Autoimmune and Oncology Biosimilars

Celltrion is consolidating its leading market position across major Asian countries with its key autoimmune and oncology therapies.
Hanmi Pharmaceutical’s Paltan Smart Plant Cuts Drug Stockouts 57% Following Reorganization

Hanmi Pharmaceutical’s Paltan Smart Plant Cuts Drug Stockouts 57% Following Reorganization

Stockout cases have dropped sharply at Hanmi Pharmaceutical’s primary manufacturing base for synthetic drugs.
Global Asset Managers Expand Holdings in South Korean Pharma and Biotech

Global Asset Managers Expand Holdings in South Korean Pharma and Biotech

Major institutional asset managers are steadily increasing their equity stakes in South Korean pharmaceutical and...
Samsung Bioepis Seeks South Korean Approval for Keytruda Biosimilar SB27

Samsung Bioepis Seeks South Korean Approval for Keytruda Biosimilar SB27

Samsung Bioepis announced on Aug. 10 that it has submitted a marketing authorization application to South Korea's...
[Reporter’s Notebook] Hanmi Group’s Internal Feuds Keep Invoking the ‘Lim Sung-ki Spirit.’ It Must Apply to Everyone

[Reporter’s Notebook] Hanmi Group’s Internal Feuds Keep Invoking the ‘Lim Sung-ki Spirit.’ It Must Apply to Everyone

Whenever a control dispute or internal conflict erupts at Hanmi Group, one phrase reliably resurfaces: the “Lim Sung-ki...
GC Biopharma Develops Advanced Platform to Track mRNA Vaccine Degradation

GC Biopharma Develops Advanced Platform to Track mRNA Vaccine Degradation

GC Biopharma has developed a technology platform capable of precisely analyzing how mRNA vaccines degrade when exposed...
Hanmi Control Dispute Reignites as Court Freezes 10 Billion Won in Lim Ju-hyun’s Shares

Hanmi Control Dispute Reignites as Court Freezes 10 Billion Won in Lim Ju-hyun’s Shares

The "four-party alliance" formed to stabilize management control at Hanmi Pharmaceutical Group has descended into open...
Alteogen Signs $365 Million Licensing Deal for Subcutaneous Drug Delivery Platform ALT-B4

Alteogen Signs $365 Million Licensing Deal for Subcutaneous Drug Delivery Platform ALT-B4

Biotechnology firm Alteogen has signed an exclusive technology-transfer agreement worth up to $365 million...
Licensing Windfalls and Exports Split Performance Among Korea’s Top Drugmakers in Q2

Licensing Windfalls and Exports Split Performance Among Korea’s Top Drugmakers in Q2

South Korea’s five major legacy pharmaceutical companies largely extended their revenue growth in the second quarter,...
Jung Yoo-seok Becomes Ilyang Pharmaceutical’s Largest Shareholder, Completing Third-Generation Succession

Jung Yoo-seok Becomes Ilyang Pharmaceutical’s Largest Shareholder, Completing Third-Generation Succession

Ilyang Pharmaceutical’s largest shareholder position has shifted from Chairman Jung Do-eon to his eldest son, CEO and...